Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease:
A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Leuco-methylthioninium bis(hydromethanesulfonate; LMTM), a stable reduced form of the methylthioninium moiety, acts as a selective inhibitor of tau protein aggregation both in…
JAMA Article on Gadolinium Exposure and Parkinson’s: A False Sense of Safety?
Welk B, McArthur E, Marrow SA, et al. Association between Gadolinium contrast Exposure and the Risk of Parkinsonism Dr. Welk and colleagues conducted a retrospective review of multiple linked administrative databases from Ontario, Canada to evaluate…
Deposition of Gadolinium in After Multiple GBCA Injections: Clinical Trial Prospective
Gadolinium-based contrast agents (GBCAs) are indispensable adjuncts to MRI, with numerous studies showing their efficacy in improving the accuracy of MRI studies. Gadolinium deposition in the brains of patients who received multiple doses of GBCAs…
RSNA 2014 Abstract: Evaluation of a New Manganese-based Orally-Administered Hepatobiliary MR Contrast Agent
To read the full article —>
RadMD Principal publishes in Nature Medicine
RadMD Principal, Rick Patt, MD was recently published in Nature Medicine magazine. The article entitled “Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer” was published in March 2013.…
RadMD Announces 2013 Webinar Series
RadMD Experts will conduct a series of Educational Webinars throughout 2013. The first in the series, “Current Issues and Role of Imaging in Alzheimer’s Disease Trials” will be hosted by Dr. Kohkan Shamsi, Principal at RadMD, on…
RadMD Receives Cum Laude Award at RSNA 2012
Dr. Richard Patt and Dr. Riccardo Lencioni were awarded the distinguished Cum Laude Award at the 98th Scientific Assembly and Annual Meeting of the RSNA 2012 in Chicago for its poster exhibit LL-GIE 4240: "Modified RECIST (mRECIST) for…
RadMD Expands Its Imaging Expertise Services with New European Office
RadMD, LLC announces the opening of its European office to expand services to EU pharma, biotech, and medical device companies.The new location will provide: A base for EU operations of consulting, training, and expert resourcing services centered…
RadMD Principals Publish in Clinical Leader
Atychiphobia: A Fear That Makes Sense When Considering Independent Reader Performance In Clinical TrialsBy Kohkan Shamsi, MD, PhD, Principal, RadMD and Rick Patt, MD, Principal, RadMD Medical imaging in clinical trials has been used as a measure of…
RadMD Principal publishes in Nature
RadMD Principal, Richard Patt, MD was recently published in Nature magazine. The article entitled "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans" was published in September 2011.Abstract: Caroline J.…